Observational study of the safety of buprenorphine+naloxone in pregnancy in a rural and remote population

Naana Afua Jumah, Craig Edwards, Jazmyn Balfour-Boehm, Kassandra Loewen, Joseph Dooley, Lianne Gerber Finn, Len Kelly, Naana Afua Jumah, Craig Edwards, Jazmyn Balfour-Boehm, Kassandra Loewen, Joseph Dooley, Lianne Gerber Finn, Len Kelly

Abstract

Objectives: To describe the effect of in utero exposure to the buprenorphine+naloxone combination product in a rural and remote population.

Setting: A district hospital that services rural and remote, fly-in communities in Northwestern Ontario, Canada.

Participants: A retrospective cohort study was conducted of 855 mother infant dyads between 1 July 2013 and 30 June 2015. Cases included all women who had exposure to buprenorphine+naloxone during pregnancy (n=62). 2 control groups were identified; the first included women with no opioid exposure in pregnancy (n=618) and the second included women with opioid exposure other than buprenorphine+naloxone (n=159). Women were excluded if they had multiple pregnancy or if they were part of a methadone programme (n=16). The majority of women came from Indigenous communities.

Outcomes: The primary outcomes were birth weight, preterm delivery, congenital anomalies and stillbirth. Secondary neonatal outcomes included gestational age at delivery, Apgar scores at 1 and 5 min, NAS Score >7 and treatment for neonatal abstinence syndrome (NAS). Secondary maternal outcomes included the number of caesarean sections, postpartum haemorrhages, out of hospital deliveries and transfer of care to tertiary centres.

Results: No difference was found in the primary outcomes or in the Apgar score and caesarean section rate between in utero buprenorphine+naloxone exposure versus no opioid exposure in pregnancy. Compared to women taking other opioids, women taking buprenorphine+naloxone had higher birthweight babies (p=0.001) and less exposure to marijuana (p<0.001) during pregnancy.

Conclusions: Retrospective data suggest that there likely is no harm from taking buprenorphine+naloxone opioid agonist treatment in pregnancy. Larger, prospective studies are needed to further assess safety.

Keywords: Buprenorphine + naloxone; Indigenous health; Pregnancy; Rural and remote; Safety.

Conflict of interest statement

Conflicts of Interest: None declared.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Figures

Figure 1
Figure 1
Patient flow chart.

References

    1. Dooley R, Dooley J, Antone I et al. . Narcotic tapering in pregnancy using long-acting morphine: an 18 month year prospective study in Northwest Ontario. Can Fam Physician 2015;61:e88–95.
    1. Walker R, Cromarty H, Kelly L et al. . Achieving Cultural Safety in Aboriginal Health Services: implementation of a cross-cultural safety model in a hospital setting. Divers Health Care 2009;6:11–22.
    1. Jones HE, Martin PR, Heil SH et al. . Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat 2008;35:245–59. 10.1016/j.jsat.2007.10.007
    1. Winklbaur B, Kopf N, Ebner N et al. . Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 2008;103:1429–40. 10.1111/j.1360-0443.2008.02283.x
    1. Katt M, Chase C, Samokhvalov A et al. . Feasibility and outcomes of a community-based taper-to-low-dose-maintenance suboxone treatment program for prescription opioid dependence in a remote First Nations community in Northern Ontario. J Aborig Health 2012;9:52–9.
    1. World Health Organization. Guidelines for the identification and management of substance use and substance use disorders in pregnancy. Geneva, Switzerland: World Health Organization, 2014:14.
    1. Wong S, Ordean A, Kahan M. Substance abuse in pregnancy. J Obstet Gynaecol Can 2011;33:367–84. 10.1016/S1701-2163(16)34855-1
    1. American College of Obstetricians and Gynecologists. Opioid abuse, dependence and addiction in pregnancy. Committee opinion 524. Obstet Gynecol 2012;119:1070–1. 10.1097/AOG.0b013e318256496e
    1. Jones HE, Kaltenbach K, Heil SH et al. . Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010;363:2320–31. 10.1056/NEJMoa1005359
    1. Daily Med. Suboxone tablet (product monograph). Bethesda (MD): National Institutes of Health, 2013. (accessed 23 Aug 2013).
    1. Daily Med. Suboxone soluble film (product monograph). Bethesda (MD): National Institutes of Health, 2013. (accessed 23 Aug 2013).
    1. Rementeriá JL, Nunag NN. Narcotic withdrawal in pregnancy: stillbirth incidence with a case report. Am J Obstet Gynecol 1973;116:1152–6. 10.1016/0002-9378(73)90953-8
    1. Stern R. The pregnant addict: a study of 66 case histories, 1950–1959. Am J Obstet Gynecol 1966;94:253–7. 10.1016/0002-9378(66)90472-8
    1. Daily Med. Naloxone hydrochloride (product monograph). Bethesda (MD): National Institutes of Health, 2013. (accessed 23 Aug 2013).
    1. Food and Drug Administration. Reviewer guidance evaluating the risks of drug exposure in human pregnancies. Rockville (MD): Food and Drug Administration, 2005:4.
    1. Indigenous and Northern Affairs Canada. Aboriginal women in Canada: a statistical profile from the 2006 census. Ottawa (ON): Government of Canada, 2012.
    1. Porter CJ, Feldt RH, Edwards WD et al. . Chapter 27: atrial septal defects. In: Allen HD, Gutgesell HP, Clark EB et al. eds. Moss & Adams’ heart disease in infants, children & adolescents: including the fetus and young adults. 8th edn Philadelphia (PA): Lippincott, Williams and Wilkins, 2013. (accessed 29 May 2016).
    1. Kelly L, Guilfoyle J, Dooley J et al. . incidence of narcotic abuse during pregnancy in Northwestern Ontario: three-year prospective cohort study. Can Fam Physician 2014;60:e493–8.
    1. Debelak K, Morrone WR, O'Grady KE et al. . Buprenorphine+naloxone in the treatment of opioid dependence during pregnancy—initial patient care and outcome data. Am J Addict 2013;22:252–4. 10.1111/j.1521-0391.2012.12005.x
    1. Lund IO, Fisher G, Welle-Strand G et al. . A Comparison of buprenorphine+naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes. Subst Abuse 2013;7:61–74. 10.4137/SART.S10955
    1. Wiegand SL, Stringer EM, Stuebe AM et al. . Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol 2015;125:363–8. 10.1097/AOG.0000000000000640
    1. Mattick RP, Breen C, Kimber J et al. . Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014;(2):CD002207 10.1002/14651858.CD002207.pub4
    1. Jumah NA, Graves L, Kahan M. The management of opioid dependence in pregnancy in rural and remote settings. CMAJ 2015;187:E41–6. 10.1503/cmaj.131723

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel